Evidence map›Paper›PMID 25469312›Full record

ArticleBioResearch open access2014

In vivo ectopic bone formation by devitalized mineralized stem cell carriers produced under mineralizing culture condition.

Yoke Chin Chai, Liesbet Geris, Johanna Bolander, Grzegorz Pyka, Simon Van Bael, Frank P Luyten, Jan Schrooten

Abstract read
In one paragraph

Article in BioResearch open access, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yoke Chin ChaiTissue Engineering Laboratory, Skeletal Biology and Engineering Research Center , KU Leuven, Leuven, Belgium . ; Department of Biomedical Engineering, Faculty of Engineering, University of Malaya , Kuala Lumpur, Malaysia . ; Prometheus, Division of Skeletal Tissue Engineering, KU Leuven , Leuven, Belgium .
Liesbet GerisPrometheus, Division of Skeletal Tissue Engineering, KU Leuven , Leuven, Belgium . ; Biomechanics Research Unit, University of Liege , Liege, Belgium .
Johanna BolanderTissue Engineering Laboratory, Skeletal Biology and Engineering Research Center , KU Leuven, Leuven, Belgium . ; Prometheus, Division of Skeletal Tissue Engineering, KU Leuven , Leuven, Belgium .
Grzegorz PykaPrometheus, Division of Skeletal Tissue Engineering, KU Leuven , Leuven, Belgium . ; Department of Materials Engineering, KU Leuven , Heverlee, Belgium .
Simon Van BaelPrometheus, Division of Skeletal Tissue Engineering, KU Leuven , Leuven, Belgium . ; Division of Production Engineering, Machine Design and Automation, Department of Mechanical Engineering, KU Leuven , Heverlee, Belgium .
Frank P LuytenTissue Engineering Laboratory, Skeletal Biology and Engineering Research Center , KU Leuven, Leuven, Belgium . ; Prometheus, Division of Skeletal Tissue Engineering, KU Leuven , Leuven, Belgium .
Jan SchrootenPrometheus, Division of Skeletal Tissue Engineering, KU Leuven , Leuven, Belgium . ; Department of Materials Engineering, KU Leuven , Heverlee, Belgium .

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Functionalization of tissue engineering scaffolds with in vitro-generated bone-like extracellular matrix (ECM) represents an effective biomimetic approach to promote osteogenic differentiation of stem cells in vitro. However, the bone-forming capacity of these constructs (seeded with or without cells) is so far not apparent. In this study, we aimed at developing a mineralizing culture condition to biofunctionalize three-dimensional (3D) porous scaffolds with highly mineralized ECM in order to produce devitalized, osteoinductive mineralized carriers for human periosteal-derived progenitors (hPDCs). For this, three medium formulations [i.e., growth medium only (BM1), with ascorbic acid (BM2), and with ascorbic acid and dexamethasone (BM3)] supplemented with calcium (Ca(2+)) and phosphate (PO4 (3-)) ions simultaneously as mineralizing source were investigated. The results showed that, besides the significant impacts on enhancing cell proliferation (the highest in BM3 condition), the formulated mineralizing media differentially regulated the osteochondro-related gene markers in a medium-dependent manner (e.g., significant upregulation of BMP2, bone sialoprotein, osteocalcin, and Wnt5a in BM2 condition). This has resulted in distinguished cell populations that were identifiable by specific gene signatures as demonstrated by the principle component analysis. Through devitalization, mineralized carriers with apatite crystal structures unique to each medium condition (by X-ray diffraction and SEM analysis) were obtained. Quantitatively, BM3 condition produced carriers with the highest mineral and collagen contents as well as human-specific VEGF proteins, followed by BM2 and BM1 conditions. Encouragingly, all mineralized carriers (after reseeded with hPDCs) induced bone formation after 8 weeks of subcutaneous implantation in nude mice models, with BM2-carriers inducing the highest bone volume, and the lowest in the BM3 condition (as quantitated by nano-computed tomography [nano-CT]). Histological analysis revealed different bone formation patterns, either bone ossicles containing bone marrow surrounding the scaffold struts (in BM2) or bone apposition directly on the struts' surface (in BM1 and BM3). In conclusion, we have presented experimental data on the feasibility to produce devitalized osteoinductive mineralized carriers by functionalizing 3D porous scaffolds with an in vitro cell-made mineralized matrix under the mineralizing culture conditions.

Indexed as

biomineralizationbone regenerationdevitalizationmineralized extracellular matrixosteoinductive carriers

Identifiers

PMID25469312
PMCPMC4245878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.